C9045 — Injection, moxetumomab pasudotox-tdfk, 0.01 mg
C9045 is a HCPCS Level II code for injection, moxetumomab pasudotox-tdfk, 0.01 mg. It belongs to the Outpatient Prospective Payment System section. It was terminated on September 30, 2019 and is not valid on new claims.
This code has been terminated
CMS terminated C9045 on September 30, 2019. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9045
- Long descriptor
- Injection, moxetumomab pasudotox-tdfk, 0.01 mg
- Short descriptor
- Moxetumomab pasudotox-tdfk
- Added
- April 1, 2019
- Terminated
- September 30, 2019
- BETOS
- O1D
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9045
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9045 is not quite right, the correct code is very often within a few positions of it.
- C9037Injection, risperidone (perseris), 0.5 mgterminated
- C9038Injection, mogamulizumab-kpkc, 1 mgterminated
- C9039Injection, plazomicin, 5 mgterminated
- C9040Injection, fremanezumab-vfrm, 1mgterminated
- C9041Injection, coagulation factor xa (recombinant), inactivated (andexxa), 10 mgterminated
- C9042Injection, bendamustine hcl (belrapzo), 1 mgterminated
- C9043Injection, levoleucovorin, 1 mgterminated
- C9044Injection, cemiplimab-rwlc, 1 mgterminated
- C9046Cocaine hydrochloride nasal solution (goprelto), 1 mg
- C9047Injection, caplacizumab-yhdp, 1 mg
- C9048Dexamethasone, lacrimal ophthalmic insert, 0.1 mgterminated
- C9049Injection, tagraxofusp-erzs, 10 mcgterminated
- C9050Injection, emapalumab-lzsg, 1 mgterminated
- C9051Injection, omadacycline, 1 mgterminated
- C9052Injection, ravulizumab-cwvz, 10 mgterminated
- C9053Injection, crizanlizumab-tmca, 1 mgterminated
Questions about C9045
What is HCPCS code C9045?
C9045 is a HCPCS Level II code for injection, moxetumomab pasudotox-tdfk, 0.01 mg. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9045?
The CMS HCPCS file marks C9045 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9045 still valid?
No. C9045 was terminated on September 30, 2019 and should not be used on new claims.